砷剂在非急性早幼粒细胞白血病血液肿瘤中的作用机制和应用前景

The Mechanism of Action and Prospective Applications of Arsenic Trioxide in Non-APL Hematologic Malignancies

关键词:  三氧化二砷  非APL血液肿瘤  作用机制  临床应用  毒性

Key words:  Arsenic Trioxide  Non-APL Hematologic Malignancies  Mechanism of Action  Clinical Application  Toxicity

摘要:

在21世纪初,三氧化二砷(As2O3,ATO)在非急性早幼粒细胞白血病(acute promyelocytic leukemia,APL)血液肿瘤的治疗中显示出新的应用前景。其通过诱导肿瘤细胞凋亡、抑制增殖等机制,为血液肿瘤治疗提供了多样化的策略。然而,ATO的应用伴随着明显的毒性,尤其是心脏副作用,这对其临床应用提出了挑战。本综述集中探讨了ATO在非APL血液肿瘤中的治疗潜力、作用机制以及毒性管理策略,旨在为医学研究者和临床医生提供治疗的深入见解,进一步优化ATO的临床应用,提高药物使用的安全性和有效性。

Abstract:

At the dawn of the 21st century, arsenic trioxide(As2O3, ATO)has emerged as a promising therapeutic agent in the treatment of hematologic malignancies other than acute promyelocytic leukemia(APL). By mechanisms such as inducing tumor cells apoptosis and inhibiting their proliferation, ATO offers a diversified strategy for the treatment of hematologic malignancies. However, the application of ATO is associated with significant toxicity, especially cardiac events, which was posing challenges to its clinical usage. This review focuses on the therapeutic potential, mechanisms of action, and toxicity management strategies of ATO in non-APL hematologic malignancies, trying to provide in-depth insights for medical researchers and clinicians to further optimize ATO's clinical applications for enhanced safety and efficacy.